Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ANDREA MIYAHIRA
The Prostate Cancer Foundation: A Discussion with Andrea Miyahira

VIEW ALL PCF VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH KENNETH PIENTA
The Process of Metastasis in Prostate Cancer

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

INTERVIEW WITH FRED SAAD
A Renewed Analysis of ERA 223

VIEW ALL ESMO VIDEOS

Featured Videos

CHICAGO, IL USA (UroToday.com) - Full Title: #ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer who have bone metastases

Presented by Daniel Petrylak, MD,1 Julie A. Rosenberg, MD,2 Vittorio Luigi Garosi, MD, PhD,3 Jonathan Siegel,2 and Jonathan Goldin, MD4 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

asco 2014 petrylak poster thumb

Click HERE to listen to an exclusive interview with Daniel Petrylak, MD, one of the authors of the study

1Yale Cancer Center, New Haven, CT USA
2Bayer HealthCare Pharmaceuticals, Inc., Whippany NJ, USA
3Bayer S.p.A., Milan, Italy
4UCLA Radiology Science, Los Angeles, CA USA

 

@UroToday
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
January 21-25, 2019 /
Mayo Clinic Urology Review 2019
January 24-27, 2019 / The Westin Riverfront at Beaver Creek
29th Annual International Prostate Cancer Update (IPCU)